Monday, June 9, 2025
Behance Facebook Instagram Linkedin Twitter Vimeo VKontakte Youtube
Home 2023

Yearly Archives: 2023

2020 Watch List

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Editor / Curator -
2023 Watch List

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical...

Editor / Curator -
2023 Watch List

Video: New Topical Drug Delivery System, NeuroDirect™

Editor / Curator -
2023 Watch List

Topical PTSD Drug Poised for Human Trials.

Editor / Curator -
Uncategorized

Ketamine and Yale University

Editor / Curator -
Zappy Zapolin, Lamar Odom, Roland Rick Perry
2023 Watch List

Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.

Editor / Curator -
AI Artificial Intelligence

Khan Academy’s AI Pilot Program.

Editor / Curator -
Biotech News

Pivotal Clinical Trials: Frequently Asked Questions (Sofpromed).

Editor / Curator -
2023 Watch List

Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.

Editor / Curator -
Accelerator

Report: Expedia, Doordash, eCommerce Fashion Retailer and YouTube All Rolled Into...

Editor / Curator -
1...111213...18Page 12 of 18

Latest article

United States Antimony (UAMY) on Fox News.

Gold Stock Analyst Editor / Curator -
DALLAS, TX / ACCESS Newswire / June 4, 2025 / United States Antimony Corporation ("USAC," "US Antimony," the "Company"), (NYSE American: UAMY), announced today that its Chairman...

Institutional Analyst: Latest Newsletter.

All News Editor / Curator -
Biotechnology, Beverages, Precious Metals, Psychedelics, and Technology. Perpetua Resources (PPTA) Joins the Billion Dollar Club Launching Institutional Gold Analyst and Gold Investor Conference1. Adding Perpetua Resources...

Blue Ocean Equities Report on Antimony.

All News Editor / Curator -
Antimony Macro Note: Don’t expect Sb prices to pull back anytime soon! ANTIMONY MACRO NOTE On Gold Investment Conference A simply fantastic report (best in world) though...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.